A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202401223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Xiao-He Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Anhui Medical University, Hefei, Anhui, 230011, China. Hauptthemen laut MEDLINE: Gene Editing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Basic Science Center Program from National Natural Science Foundation of China, Natural Science Research Project of Anhui Province Colleges and Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer immunotherapy, which aims to eliminate cancer immunosuppression and reactivate anticancer immunity, holds great promise in oncology treatments. However, it is challenging to accurately study the efficacy of immunotherapy based on human‐derived cells through animal experiments due to xenogeneic immune rejection. Herein, a personalized and precise strategy to evaluate the effectiveness of immunotherapy using the blood samples of cancer patients is presented. Through the utilization of multiple cancer‐targeting delivery system decorated with the epidermal growth factor receptor (EGFR)‐specific aptamer CL4 and the AXL‐specific aptamer GL21.T to achieve superior efficiency in delivering the genome editing plasmid for MUC1 knockout, effective modulation on the behavior of circulating malignant cells (CMCs) is realized. After genome editing, both mucin 1 (MUC1) and programmed death‐ligand 1 (PD‐L1) are significantly downregulated in CMCs. The elimination of immunosuppression results in markedly enhanced secretion of pro‐inflammatory anticancer cytokines encompassing interleukins 2, 12, and 15 and interferon‐γ by immune cells. The study not only provides a strategy to overcome immunosuppression but also yields critical insights for personalized immunotherapy approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Anhui Medical University, Hefei, Anhui, 230011, China.
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, 430072, China.
- Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, Hefei, Anhui, 230011, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, Hefei, Anhui, 230011, China.
ORCID-Profile: Yun Huang, Si-Xue Cheng
Förderung
- Basic Science Center Program from National Natural Science Foundation of China
- Natural Science Research Project of Anhui Province Colleges and Universities
- National Natural Science Foundation of China
Zitieren
APA
Ren, X. H., Guo, T., Xu, M. F., Huang, Y., Liao, X. R., Qi, L. J., & Cheng, S. X. (2025). A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401223
Vancouver
Ren XH, Guo T, Xu MF, Huang Y, Liao XR, Qi LJ, et al. A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202401223
BibTeX
@article{Ren2025,
author = {Ren, Xiao-He and Guo, Tao and Xu, Ma-Fei and Huang, Yun and Liao, Xin-Ru and Qi, Li-Jin and Cheng, Si-Xue},
title = {A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202401223}
}
EUVIMED